(Corrects to show company’s plan for acquisition procedures in third paragraph.)
Sept. 28 (Bloomberg) -- Santen Pharmaceutical Co. plans to acquire France’s Novagali Pharma SA for as much as 102 million euros ($139 million).
The Japanese drugmaker agreed to acquire 50.55 percent of Novagali from its existing shareholders, according to a statement to the Tokyo Stock Exchange today. Santen will also launch a tender offer of 6.15 euros for each Novagali share for the rest of the holdings.
If Santen acquires at least 95 percent of Novagali, the drugmaker will increase the amount paid to 6.25 euros a share, the statement said.
To contact the reporter on this story: Go Onomitsu in Tokyo at email@example.com
To contact the editor responsible for this story: Gearoid Reidy at firstname.lastname@example.org